Compare ADMA Biologics Inc (ADMA) vs Abercrombie & Fitch Co. (ANF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Abercrombie & Fitch Co. — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Abercrombie & Fitch Co. trades at $86.37 (market cap $3.96B). The key difference: Abercrombie & Fitch Co. is the larger of the two by market cap, and Abercrombie & Fitch Co. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ANF | |
|---|---|---|
Market Cap | $2.13B | $3.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $129.85 |
52-Week Low | $7.60 | $65.61 |
Enterprise Value | $2.20B | $4.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ANF trades at $89.07, down 3.61% today but maintains strong fundamentals with a P/E of 8.68 and robust profitability metrics including 39.04% ROE. The stock shows technical bullish signals with support at $88 and resistance at $92. Recent earnings beats and 2025 revenue growth to $4.95B demonstrate operational strength, while expansion into third-party footwear and Target partnerships highlight growth initiatives.
ANF presents a compelling value opportunity with attractive valuation multiples and consistent earnings outperformance. Key risks include moderating sales growth and international market softness. Analyst consensus price target of $107.71 suggests 21% upside potential, supported by strong institutional sentiment despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →
